Breathe Well Live Well
|
Breathable treatment to help prevent asthma attacks
Medical Xpress He continues: "Southampton researchers, working alongside asthma patients, made the original discovery that weakened immunity amongst asthmatics was key to viral impacts; now study participants are helping us to confirm that discovery and translate it … Synairgen presents proof of concept study |
View full post on asthma – Google News
|
Breathable treatment to help prevent asthma attacks
Science Codex Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September. The study … Synairgen presents proof of concept study |
View full post on asthma – Google News
|
GSK drug halves attacks in hard-to-treat asthma
Business Recorder (blog) An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success. Britain's biggest … |
View full post on asthma – Google News
 Telegraph.co.uk |
Experimental Asthma Drug Halves Attacks
The Inquisitr The Telegraph reports the medicine is called mepolizumab and treats a rare form of the condition in which white blood cells called eosinophils cause lung airways to become inflamed. The new asthma drug is injected, and reduces the number of eosinophils … Glaxo's Experimental Drug Halves Asthma Attacks in Study Experimental Drug May Cut Severe Asthma Attacks: Study GSK drug halves attacks in hard-to-treat asthma |
View full post on asthma – Google News
|
Experimental Drug May Cut Severe Asthma Attacks: Study
iVillage Entertainment THURSDAY, Aug. 16 (HealthDay News) — An experimental drug known as mepolizumab may reduce outbreaks by almost 50 percent in people with a type of hard-to-treat asthma, an early study finds. About a third of people with severe asthma have what is … |
View full post on asthma – Google News
 Telegraph.co.uk |
Glaxo's Experimental Drug Halves Asthma Attacks in Study
Businessweek Among 621 participants with severe asthma, after a year of treatment, the rate of attacks requiring oral corticosteroids, emergency room visits or hospitalizations was about half for those taking one of three monthly doses of the drug, called … Experimental Drug May Cut Severe Asthma Attacks: Study GSK drug halves attacks in hard-to-treat asthma Experimental drug halves attacks in hard-to-treat asthma |
View full post on asthma – Google News
Telegraph.co.uk |
GlaxoSmithKline asthma drug cuts number of attacks
Telegraph.co.uk He said: “It seems to be a safe and effective treatment option for patients with eosinophilic asthma that is associated with frequent flare-ups, and may reduce the need for conventional treatment with oral corticosteroids that can have serious side … |
View full post on asthma – Google News
Telegraph.co.uk |
Experimental Drug May Cut Severe Asthma Attacks: Study
U.S. News & World Report About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take … Experimental drug halves attacks in hard-to-treat asthma GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma |
View full post on asthma – Google News
Telegraph.co.uk |
Experimental Drug May Cut Severe Asthma Attacks: Study
Philadelphia Inquirer About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take … Experimental drug halves attacks in hard-to-treat asthma GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma |
View full post on asthma – Google News
Telegraph.co.uk |
Experimental drug halves attacks in hard-to-treat asthma
Fox News The injectable antibody treatment mepolizumab is designed to help a small group of people with asthma in which white blood cells called eosinophils cause inflammation of lung airways. It reduces the number of eosinophils by inhibiting an immune system … GSK drug halves attacks in hard-to-treat asthma GSK runs to Ph3 with upbeat data on drug for severe asthma Experimental Drug May Cut Severe Asthma Attacks: Study |
View full post on asthma – Google News